

Sarah Costantino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3833928/publications.pdf>

Version: 2024-02-01

49
papers

1,885
citations

236612

25
h-index

264894

42
g-index

49
all docs

49
docs citations

49
times ranked

3000
citing authors

#	ARTICLE	IF	CITATIONS
1	Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. <i>Cardiovascular Research</i> , 2023, 118, 3374-3385.	1.8	10
2	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. <i>Cardiovascular Research</i> , 2022, 118, 2385-2396.	1.8	14
3	The BET Protein Inhibitor Apabetalone Rescues Diabetes-Induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 667-684.	2.5	15
4	Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system. <i>Cardiovascular Research</i> , 2021, 117, 2275-2288.	1.8	13
5	Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?. <i>Cardiovascular Research</i> , 2021, 117, 343-345.	1.8	3
6	Epigenetic Remodeling in Obesity-Related Vascular Disease. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1165-1199.	2.5	19
7	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. <i>European Heart Journal</i> , 2021, 42, 1940-1958.	1.0	34
8	Disentangling the epigenetic landscape in cardiovascular patients: a path toward personalized medicine. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 331-345.	0.4	6
9	Inflammation in Metabolic Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 742178.	1.1	42
10	Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood-brain barrier integrity: a translational study. <i>European Heart Journal</i> , 2020, 41, 1575-1587.	1.0	54
11	MicroRNA-122 in heart failure with reduced ejection fraction: Epiphenomenon or causal?. <i>International Journal of Cardiology</i> , 2020, 303, 66-67.	0.8	1
12	Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3. <i>Thrombosis and Haemostasis</i> , 2020, 120, 168-180.	1.8	13
13	New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 363-371.	1.0	12
14	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020, 127, 1261-1273.	2.0	38
15	Epigenetic Control of Mitochondrial Function in the Vasculature. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 28.	1.1	39
16	Regression of left ventricular hypertrophy with SGLT2 inhibitors. <i>European Heart Journal</i> , 2020, 41, 3433-3436.	1.0	11
17	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis - Central role of macrophage scavenger receptor 1. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 139, 24-32.	0.9	26
18	The vascular epigenome in patients with obesity and type 2 diabetes: opportunities for personalized therapies. <i>Vascular Biology (Bristol, England)</i> , 2020, 2, H19-H28.	1.2	6

#	ARTICLE	IF	CITATIONS
19	Sex-related differences in the ageing brain: time for precision medicine?. <i>Cardiovascular Research</i> , 2020, 116, 1246-1248.	1.8	2
20	The Epigenome in Atherosclerosis. <i>Handbook of Experimental Pharmacology</i> , 2020, , 511-535.	0.9	5
21	PCSK9 in diabetes: sweet, bitter or sour?. <i>European Heart Journal</i> , 2019, 40, 369-371.	1.0	8
22	GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials. <i>Vascular Pharmacology</i> , 2019, 115, 64-68.	1.0	6
23	Epigenetic modulation of tenascin C in the heart. <i>Journal of Hypertension</i> , 2019, 37, 1861-1870.	0.3	19
24	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. <i>European Heart Journal</i> , 2019, 40, 997-1008.	1.0	69
25	Epigenetic processing in cardiometabolic disease. <i>Atherosclerosis</i> , 2019, 281, 150-158.	0.4	44
26	Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies. <i>European Heart Journal</i> , 2019, 40, e11-e13.	1.0	1
27	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , 2019, 40, 383-391.	1.0	45
28	Atrial fibrillation in the cardiometabolic patient. <i>Minerva Medica</i> , 2019, 110, 157-167.	0.3	12
29	Stem cell therapy in heart failure: Is the best yet to come?. <i>International Journal of Cardiology</i> , 2018, 260, 135-136.	0.8	2
30	Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. <i>European Heart Journal</i> , 2018, 39, 4150-4158.	1.0	79
31	Epigenetics and cardiovascular regenerative medicine in the elderly. <i>International Journal of Cardiology</i> , 2018, 250, 207-214.	0.8	41
32	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc. <i>International Journal of Cardiology</i> , 2018, 268, 179-186.	0.8	47
33	The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. <i>Kidney International</i> , 2018, 94, 49-59.	2.6	62
34	Authors' reply to Dr. Schmitz and Dr. Brand comments on "Epigenetics and Cardiovascular Regenerative Medicine in the Elderly". <i>International Journal of Cardiology</i> , 2018, 257, 274.	0.8	0
35	Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways. <i>Cardiovascular Research</i> , 2017, 113, 498-507.	1.8	27
36	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels. <i>Diabetes</i> , 2017, 66, 2472-2482.	0.3	139

#	ARTICLE	IF	CITATIONS
37	Ageing, metabolism and cardiovascular disease. <i>Journal of Physiology</i> , 2016, 594, 2061-2073.	1.3	311
38	Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. <i>International Journal of Cardiology</i> , 2016, 203, 702-707.	0.8	39
39	Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. <i>European Heart Journal</i> , 2016, 37, 1733-1737.	1.0	27
40	MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. <i>European Heart Journal</i> , 2016, 37, 572-576.	1.0	136
41	Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 150-158.	5.1	141
42	Molecular pathways of arterial aging. <i>Clinical Science</i> , 2015, 128, 69-79.	1.8	42
43	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , 2015, 36, 817-828.	1.0	75
44	Hyperglycemia: a bad signature on the vascular system. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 403-6.	0.7	17
45	Role of oxidative stress in endothelial insulin resistance. <i>World Journal of Diabetes</i> , 2015, 6, 326.	1.3	51
46	Diabetes and cardiovascular disease: let's push forward with translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 407-11.	0.7	4
47	p66Shc-induced redox changes drive endothelial insulin resistance. <i>Atherosclerosis</i> , 2014, 236, 426-429.	0.4	31
48	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 324-32.	0.7	30
49	Epi-Drugs in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	17